Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006221 · ClinicalTrials.gov registry record · Phase 1
BMS-247550 in Treating Patients With Advanced Cancers
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT00006221: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00006221 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006221, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of BMS-247550 in treating patients who have malignant solid tumors or lymphoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Interventions
- DRUG ixabepilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2000-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006221
The ClinicalTrials.gov registry entry for NCT00006221 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ixabepilone is the first listed.
NCT00006221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006221 about?
NCT00006221 is a clinical study titled "BMS-247550 in Treating Patients With Advanced Cancers". Phase I trial to study the effectiveness of BMS-247550 in treating patients who have malignant solid tumors or lymphoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
What is the current status of trial NCT00006221?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2000-11.
What interventions are being tested in trial NCT00006221?
The interventions under investigation include: ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00006221?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.